Gilead makes brave decision: announces launch of generics to Harvoni and Epclusa

Gilead Sciences has announced it has created the subsidiary Asegua Therapeutics LLC, a company that will distribute generics–specifically  Epclusa (sofosbuvir 400mg/velpatasvir 100mg) and Harvoni (ledipasvir 90mg/sofosbuvir 400mg). The two drugs are the group’s blockbusters for hepatitis C, and their sales have plunged due to cheaper solutions by competitors. The generics will be available as early as January, at  $24,000 per treatment, which is below the $26,400 set by competitor AbbVie for Mavyret. The market has clearly approved Gilead’s strategy, indeed its shares have risen by 0.7%, in sharp contrast to market trends.

(Source: Gilead)